Meister Keith A. sold $85.2M of ILMN (indirect holdings)

Meister Keith A. sold 375,941 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $226.74 ($224.72–$231.23, $85.24M total) across 13 trades over 2026-08-25 to 2026-08-27.

Original reporting
SEC EDGAR · Meister Keith A.
Published Aug 27, 2026, 11:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Bearish
medium confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNBearishLow
01

Why it matters

The sizable director sale could trigger short interest and affect short‑term price dynamics.

02

Market read

Material insider sell by a director is a notable event for traders monitoring ILMN.

03

What to watch

The sale was executed via a 10b5‑1 plan, indicating pre‑planned execution rather than reaction to new information.

Relevance 8/10Novelty 8/10Timing: Filed Aug 27 2026 (Form 4 filing date)

Background

SEC Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$ILMNBearishMedium confidence
Context

Director Meister Keith A. sold 375,941 shares for $85.2M, reducing his stake to 1,033,910 shares.

Expected impact

Potential short-term downside of 2‑4% as market digests the sale.

Evidence & confidence

The $85M sale by a director is material and likely to be viewed negatively by investors.

Market effects

May weigh on other genomics and diagnostics stocks as investors reassess insider sentiment.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond Illumina and its peers.

Counterpoint

Insider may be diversifying portfolio; sale does not necessarily reflect company fundamentals.

Key entities

  • Illumina, Inc.

    US‑listed genomics and diagnostics firm (ticker ILMN).

  • Meister Keith A.

    Director of Illumina who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.